Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics has begun enrolling patients in a phase II clinical trial of Xcytrin injection, the company's lead therapeutic candidate for the treatment of brain metastases from solid tumors, or cancer that has spread to the brain.
Subscribe to our email newsletter
The trial, which will enroll 45 patients at 14 medical centers across the US and Canada, will evaluate Xcytrin in combination with whole brain radiation therapy and stereotactic radiosurgery.
“For select patients with a limited number of brain metastases, stereotactic radiosurgery is becoming a widely-used treatment. This trial is intended to demonstrate that Xcytrin can improve treatment outcome in patients with brain metastases who are treated with stereotactic radiosurgery,” said Dr Minesh Mehta, professor and chairman of human oncology at the University of Wisconsin Medical School.
Dr Mehta also said that the study should show that Xcytrin can be used alongside magnetic resonance imaging to produce better images of tumors and help radiosurgeons to define the treatment field.